$151 Million is the total value of Opus Point Partners Management, LLC's 57 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 80.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IBB | Buy | ISHARES TRnasdq biotec etf | $10,691,000 | +76.2% | 31,600 | +58.0% | 7.06% | +110.8% |
| ALKS | Buy | ALKERMES PLC | $6,939,000 | +36.2% | 87,415 | +0.6% | 4.58% | +62.9% |
| IONS | New | IONIS PHARMACEUTICALS INC | $6,345,000 | – | 102,459 | +100.0% | 4.19% | – |
| REGN | Buy | REGENERON PHARMACEUTICALS | $5,816,000 | +17.7% | 10,714 | +0.8% | 3.84% | +40.8% |
| AMGN | Buy | AMGEN INC | $5,807,000 | +646.4% | 35,773 | +535.9% | 3.84% | +792.1% |
| CELG | Buy | CELGENE CORP | $5,743,000 | +12.6% | 47,956 | +1.7% | 3.79% | +34.8% |
| SGEN | Buy | SEATTLE GENETICS INC | $5,704,000 | +18.8% | 127,088 | +2.0% | 3.77% | +42.1% |
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $5,304,000 | +148.9% | 77,100 | +114.2% | 3.50% | +197.7% |
| VRTX | Buy | VERTEX PHARMACEUTICALS INC | $5,242,000 | +23.1% | 41,662 | +1.9% | 3.46% | +47.3% |
| INCY | Buy | INCYTE CORP | $5,210,000 | -0.4% | 48,045 | +1.4% | 3.44% | +19.2% |
| MRK | Buy | MERCK & CO INC NEW | $4,754,000 | +134.8% | 90,000 | +119.5% | 3.14% | +180.9% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $4,728,000 | +21.4% | 50,222 | +3.7% | 3.12% | +45.3% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $4,596,000 | +3.9% | 43,870 | +4.4% | 3.04% | +24.3% |
| GILD | Buy | GILEAD SCIENCES INC | $3,410,000 | +704.2% | 33,700 | +679.6% | 2.25% | +862.8% |
| ADMS | New | ADAMAS PHARMACEUTICALS INC | $2,266,000 | – | 80,000 | +100.0% | 1.50% | – |
| EPZM | Buy | EPIZYME INC | $2,173,000 | +266.4% | 135,627 | +194.3% | 1.44% | +339.1% |
| LOXO | New | LOXO ONCOLOGY INC | $1,707,000 | – | 60,000 | +100.0% | 1.13% | – |
| ZGNX | Buy | ZOGENIX INC | $1,411,000 | +59.1% | 95,700 | +45.7% | 0.93% | +90.2% |
| RXDX | New | IGNYTA INC | $1,340,000 | – | 100,000 | +100.0% | 0.88% | – |
| OPHT | Buy | OPHTHOTECH CORP | $1,335,000 | +360.3% | 17,000 | +137.8% | 0.88% | +451.2% |
| XNCR | New | XENCOR INC | $1,316,000 | – | 90,000 | +100.0% | 0.87% | – |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $1,187,000 | – | 100,000 | +100.0% | 0.78% | – |
| MCRB | New | SERES THERAPEUTICS INC | $1,158,000 | – | 33,000 | +100.0% | 0.76% | – |
| PRTK | New | PARATEK PHARMACEUTICALS INC | $1,138,000 | – | 60,000 | +100.0% | 0.75% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALS | $1,032,000 | – | 100,000 | +100.0% | 0.68% | – |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $1,020,000 | +39.5% | 6,514 | +16.9% | 0.67% | +66.8% |
| MACK | Buy | MERRIMACK PHARMACEUTICALS IN | $968,000 | +83.3% | 122,500 | +97.6% | 0.64% | +118.8% |
| MDCO | New | MEDICINES CO | $934,000 | – | 25,000 | +100.0% | 0.62% | – |
| MGNX | New | MACROGENICS INC | $929,000 | – | 30,000 | +100.0% | 0.61% | – |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $795,000 | +412.9% | 60,000 | +306.8% | 0.52% | +510.5% |
| FLDM | Buy | FLUIDIGM CORP DEL | $757,000 | +520.5% | 70,000 | +366.7% | 0.50% | +646.3% |
| TKAI | New | TOKAI PHARMACEUTICALS INC | $541,000 | – | 62,007 | +100.0% | 0.36% | – |
| DNAI | New | PRONAI THERAPEUTICS INC | $451,000 | – | 30,000 | +100.0% | 0.30% | – |
| DPRX | New | DIPEXIUM PHARMACEUTICALS INC | $280,000 | – | 25,000 | +100.0% | 0.18% | – |
| CBYL | New | CARBYLAN THERAPEUTICS INC | $63,000 | – | 17,500 | +100.0% | 0.04% | – |
| RPRXZ | New | REPROS THERAPEUTICS INCcall | $33,000 | – | 98,000 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.